The public offer by Alexion Pharmaceuticals, Inc. through Alexion Pharma Nordics Holding AB (“Alexion”) for the shares in Wilson Therapeutics AB (publ) (“Wilson”) was declared unconditional today, 25 May 2018. Alexion owns more than 90 per cent of the shares in Wilson and intends to request compulsory acquisition in respect of the remaining shares in Wilson. The acceptance period for Alexion’s offer has been extended up to and including 8 June 2018, 3:00 p.m. CET, to allow remaining shareholders in Wilson to accept the offer.

At the request of Alexion, the Board of Directors of Wilson has resolved to apply for delisting of Wilson’s shares from Nasdaq Stockholm. The last day of trading in Wilson’s shares on Nasdaq Stockholm will be announced as soon as Wilson has received confirmation of such date from Nasdaq Stockholm.